163 related articles for article (PubMed ID: 12151864)
1. High-sensitivity C-reactive protein and cardiovascular risk in patients with coronary heart disease.
Rosenson RS; Koenig W
Curr Opin Cardiol; 2002 Jul; 17(4):325-31. PubMed ID: 12151864
[TBL] [Abstract][Full Text] [Related]
2. High-sensitivity C-reactive protein in the prediction of coronary events in patients with premature coronary artery disease.
Speidl WS; Graf S; Hornykewycz S; Nikfardjam M; Niessner A; Zorn G; Wojta J; Huber K
Am Heart J; 2002 Sep; 144(3):449-55. PubMed ID: 12228781
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of high-sensitivity C-reactive protein in predicting long-term risk of death or acute myocardial infarction in patients with unstable or stable angina pectoris or acute myocardial infarction.
Zebrack JS; Anderson JL; Maycock CA; Horne BD; Bair TL; Muhlestein JB;
Am J Cardiol; 2002 Jan; 89(2):145-9. PubMed ID: 11792332
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina.
Liuzzo G; Biasucci LM; Gallimore JR; Grillo RL; Rebuzzi AG; Pepys MB; Maseri A
N Engl J Med; 1994 Aug; 331(7):417-24. PubMed ID: 7880233
[TBL] [Abstract][Full Text] [Related]
5. [Inflammation study in unstable angina and myocardial infarction without ST segment elevation. Value of ultra-sensitive C-reactive protein].
Borrás Pallé S; Gómez Martínez E; Romero Rodrigo A; Campos Ferrer C; Molina E; Valentín Segura V
An Med Interna; 2002 Jun; 19(6):283-8. PubMed ID: 12152386
[TBL] [Abstract][Full Text] [Related]
6. [Markers of inflammatory process in stable and unstable coronary artery disease].
Okopień B; Basiak M; Madej A; Labuzek K; Belowski D; Haberka M; Herman ZS
Pol Merkur Lekarski; 2006 Jul; 21(121):69-72. PubMed ID: 17007298
[TBL] [Abstract][Full Text] [Related]
7. Erythrocyte sedimentation rate as a marker for coronary heart disease.
Yayan J
Vasc Health Risk Manag; 2012; 8():219-23. PubMed ID: 22536077
[TBL] [Abstract][Full Text] [Related]
8. C-reactive protein as a marker for acute coronary syndromes.
Mach F; Lovis C; Gaspoz JM; Unger PF; Bouillie M; Urban P; Rutishauser W
Eur Heart J; 1997 Dec; 18(12):1897-902. PubMed ID: 9447317
[TBL] [Abstract][Full Text] [Related]
9. C-reactive protein and the severity of atherosclerosis in myocardial infarction patients with stable angina pectoris.
Tataru MC; Heinrich J; Junker R; Schulte H; von Eckardstein A; Assmann G; Koehler E
Eur Heart J; 2000 Jun; 21(12):1000-8. PubMed ID: 10901512
[TBL] [Abstract][Full Text] [Related]
10. Serum Fas/FasL levels in dependence on clinical presentations of coronary disease and their relationship with risk factors.
Ristić T; Djordjević VB; Deljanin-Ilić M; Cosić V; Kundalić S
Vojnosanit Pregl; 2010 Jul; 67(7):537-42. PubMed ID: 20707047
[TBL] [Abstract][Full Text] [Related]
11. C-reactive protein and coronary artery disease.
Auer J; Berent R; Lassnig E; Eber B
Jpn Heart J; 2002 Nov; 43(6):607-19. PubMed ID: 12558125
[TBL] [Abstract][Full Text] [Related]
12. Elevated serum neopterin predicts future adverse cardiac events in patients with chronic stable angina pectoris.
Avanzas P; Arroyo-Espliguero R; Quiles J; Roy D; Kaski JC
Eur Heart J; 2005 Mar; 26(5):457-63. PubMed ID: 15684278
[TBL] [Abstract][Full Text] [Related]
13. [Endothelin and big endothelin in coronary heart disease and acute coronary syndromes].
Borries M; Heins M; Fischer Y; Stiegler H; Schoebel FC; Reinauer H; Strauer BE; Leschke M
Z Kardiol; 1996 Oct; 85(10):761-7. PubMed ID: 9036701
[TBL] [Abstract][Full Text] [Related]
14. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: clinical use of inflammatory markers in patients with cardiovascular diseases: a background paper.
Biasucci LM; ;
Circulation; 2004 Dec; 110(25):e560-7. PubMed ID: 15611382
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial.
Held C; White HD; Stewart RAH; Budaj A; Cannon CP; Hochman JS; Koenig W; Siegbahn A; Steg PG; Soffer J; Weaver WD; Östlund O; Wallentin L;
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29066452
[TBL] [Abstract][Full Text] [Related]
16. Inflammatory markers and coronary heart disease.
Rifai N; Ridker PM
Curr Opin Lipidol; 2002 Aug; 13(4):383-9. PubMed ID: 12151853
[TBL] [Abstract][Full Text] [Related]
17. Brain natriuretic peptide and other risk markers for outcome assessment in patients with non-ST-elevation coronary syndromes and preserved systolic function.
Palazzuoli A; Deckers J; Calabrò A; Campagna MS; Nuti R; Pastorelli M; Pasqui AL; Bruni F; Auteri A; Puccetti L
Am J Cardiol; 2006 Nov; 98(10):1322-8. PubMed ID: 17134622
[TBL] [Abstract][Full Text] [Related]
18. Risk stratification and prognostic implication of plasma biomarkers in nondiabetic patients with stable coronary artery disease: the role of high-sensitivity C-reactive protein.
Leu HB; Lin CP; Lin WT; Wu TC; Chen JW
Chest; 2004 Oct; 126(4):1032-9. PubMed ID: 15486359
[TBL] [Abstract][Full Text] [Related]
19. Impact of C-reactive protein and fibrinogen on cardiovascular prognosis in patients with stable angina pectoris: the AtheroGene study.
Sinning JM; Bickel C; Messow CM; Schnabel R; Lubos E; Rupprecht HJ; Espinola-Klein C; Lackner KJ; Tiret L; Münzel T; Blankenberg S;
Eur Heart J; 2006 Dec; 27(24):2962-8. PubMed ID: 17132649
[TBL] [Abstract][Full Text] [Related]
20. [Related inflammation markers among different types of coronary heart disease].
Luo Y; Xie XM; Liu HX
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2004 Apr; 29(2):227-9. PubMed ID: 16145923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
